BeyondSpring (BYSI) Research & Development (2016 - 2026)
BeyondSpring's (BYSI) quarterly Research & Development came in at $973000.0 in Q2 2026, down 2.89% year-over-year from $1.0 million in Q2 2025, and down 9.57% quarter-over-quarter from $1.1 million in Q1 2026.
Powered by 
Analysis
BeyondSpring (BYSI) Research & Development (2016 - 2026) Analysis & Trends
BeyondSpring has disclosed Research & Development across 9 years of filings, most recently posting $973000.0 for Q2 2026.
- In Q2 2026, Research & Development fell 2.89% year-over-year to $973000.0; the TTM figure through Jun 2026 stood at $4.6 million (up 53.57% YoY), while the FY2025 annual figure was $4.4 million, up 65.96% from the prior year.
- Research & Development came in at $973000.0 for Q2 2026 at BeyondSpring, down from $1.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $1.5 million in Q4 2025 to a low of $472000.0 in Q4 2024.
- Average Research & Development over 3 years is $908100.0, with a median of $923500.0 recorded in 2025.
- Year-over-year, Research & Development soared 212.08% in 2025 and fell 2.89% in 2026.
- Over 3 years, Research & Development stood at $472000.0 in 2024, then soared by 212.08% to $1.5 million in 2025, then tumbled by 33.94% to $973000.0 in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $973000.0 in Q2 2026, $1.1 million in Q1 2026, and $1.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 2.81 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | -2.60 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | 394.92 Mn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 516.95 Mn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 146.30 Mn |
| 10 | BeyondSpring | 31.51 Mn | 31.51 Mn | - | 973,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 973,000.00 |
| Mar 31, 2026 | 1.08 Mn |
| Dec 31, 2025 | 1.47 Mn |
| Sep 30, 2025 | 1.04 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 874,000.00 |
| Dec 31, 2024 | 472,000.00 |
| Sep 30, 2024 | 622,000.00 |
| Jun 30, 2024 | 829,000.00 |
| Mar 31, 2024 | 721,000.00 |
| Dec 31, 2021 | 5.79 Mn |
| Sep 30, 2021 | 8.46 Mn |
| Jun 30, 2021 | 11.33 Mn |
| Mar 31, 2021 | 11.31 Mn |
| Dec 31, 2020 | 8.42 Mn |
| Sep 30, 2020 | 8.64 Mn |
| Jun 30, 2020 | 11.03 Mn |
| Mar 31, 2020 | 13.70 Mn |
| Dec 31, 2019 | 12.58 Mn |
| Sep 30, 2019 | 7.23 Mn |